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M
oderate insulin resistance is a physiological attribute of advancing pregnancy to maintain an optimal materno-fetal nutrient supply (1) . Disturbances in this process can promote the development of gestational diabetes mellitus (GDM), one of the most prevalent diseases in pregnancy (2) (3) (4) . GDM is associated with detrimental health outcomes in both mother and child (5) . Beyond defects in insulin secretion, failed responses of target tissues to the insulin signaling represent a hallmark of GDM. However, the underlying molecular mechanisms of tissue-specific insulin resistance remain poorly understood.
The insulin receptor (IR) is pivotal in transmitting insulin's decisive effects on glucose and lipid metabolism and energy homeostasis. Dysfunction of the insulinsignaling pathway has been implicated as major driver for cellular insulin resistance, promoting the development of metabolic disorders and diseases (6) . Interestingly, studies in insulin-resistant subjects with obesity and patients with type 2 diabetes suggest that such defects occur predominately in postreceptor signals and not primarily at the IR level itself (7) . In GDM, however, few investigations have addressed potential alterations of the IR and its downstream effectors in insulin-sensitive tissues [e.g., skeletal muscle, placenta, subcutaneous adipose tissue (SAT)] (8) (9) (10) (11) (12) . Indeed, postreceptor defects were present across all these tissues in women with GDM, in particular with regard to IR substrate 1 and phosphatidylinositol 3-kinase p85a expression and tyrosine phosphorylation (8, (10) (11) (12) . Furthermore, patients with GDM had impaired IR activity (specifically, tyrosine phosphorylation) in skeletal muscle and adipocytes (8, 9) . However, expression analyses of IR yielded inconsistent results. In skeletal muscle and SAT, IR protein levels were similar or decreased in women with GDM (8, 10, 12) . Beyond skeletal muscle, a major tissue for whole-body glucose disposal, adipose tissue (AT) has been recognized as a vital metabolic and endocrine organ that has profound effects on local and systemic insulin sensitivity (13, 14) . Remarkably, although visceral adipose tissue (VAT) is considered more metabolically active and more strongly associated with insulin resistance than is SAT (15, 16) , studies are lacking on VAT in GDM with respect to the insulin-signaling pathway. Therefore, a comprehensive investigation on SAT and VAT IR expression may provide valuable insights into molecular mechanisms of insulin resistance in GDM.
DNA methylation is a key epigenetic regulator critically involved in the transcriptional machinery (17) . Although the function of DNA methylation is complex and still not completely understood, higher methylation of cytosine-phosphate-guanine (CpG) dinucleotides in promoter regions has been commonly associated with repression of gene transcription (17) . Depending on the region, DNA methylation patterns occur in a tissuespecific manner but can also show similar profiles across tissues (e.g., with circulating blood cells), which would be beneficial for clinical and experimental approaches. To date, however, the human IR DNA methylation pattern and potential alterations in metabolic diseases have not been investigated, to our knowledge.
Offspring of diabetic mothers (ODM) show increased susceptibility for the development of glucose intolerance and associated disturbances later in life (5, 18) . Underlying molecular mechanisms remain unclear. Epigenetic mechanisms such as DNA methylation may represent a key factor within the complexity of perinatal programming of so-called diabesity in ODM (19, 20) . Because DNA methylation is considered a relatively stable epigenetic mark, alterations may have lasting influences on respective gene expression and, therefore, provide an interesting target for investigations of both diabetic mothers and their affected offspring.
Thus, we analyzed IR mRNA and protein expression in SAT and VAT biopsy specimens from women with GDM and matched control subjects. In parallel, we characterized DNA methylation profiles across IR promoter and intronic regions in maternal ATs and blood cells, as well as cord-blood (CB) samples. Finally, we evaluated alterations of the DNA methylation patterns with respect to gene expression and/or phenotypic parameters in mothers and offspring.
Material and Methods
The mother-child dyads we investigated are part of the prospective observational Early Charité Cohort Study (21) . Twenty-five women with GDM and 30 women with normal glucose tolerance (NGT) were prospectively recruited before scheduled delivery of singletons via cesarean delivery at the Clinic of Obstetrics, Charité -Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany. Information about recruitment, exclusion criteria, standardized procedures, analytical methods, and so on were described previously (21) .
The GDM and NGT groups were matched for maternal age, ethnic origin, socioeconomic status, parity, and, in particular, prepregnancy body mass index (BMI). The study was performed in accordance with the Declaration of Helsinki and approved by the local Ethics Committee (no. EA2/026/04). All subjects gave written informed consent prior to study inclusion.
Subject data and GDM screening
Maternal and offspring data were collected as described by Ott et al. (21) . GDM screening was performed between the 24th and 28th weeks of gestation, according to national guidelines at the time of recruitment (22, 23) . To achieve the instructed glucose targets (22, 23) , women with GDM were treated either by diet alone or in combination with insulin therapy (n = 13).
Tissue sampling and plasma measurements
Paired abdominal SAT and omental VAT biopsy specimens were obtained from the mothers during cesarean delivery, snap frozen in liquid nitrogen, and stored at 280°C. For technical reasons, one VAT sample of one study subject with GDM was lost. Fasting maternal venous blood (MB) was collected in a 10-mL EDTA-coated vacutainer (BD, Franklin Lakes, NJ) before cesarean delivery, and venous umbilical cord blood (CB) was collected immediately after birth and cord clamping into 10-mL EDTA-coated blood collection tubes (BD). For additional analyses, fractions of plasma and mixed blood cells were stored at 280°C.
Plasma insulin and C-peptide concentrations were measured by commercially available radioimmunoassays according to manufacturer's protocol (insulin: catalog no. RIA-1249, C-peptide: catalog no. RIA-1252; DRG Instruments, Marburg, Germany). The interassay coefficients of variance were 3.4% to 6.0% and 2.4% to 9.3% for insulin and C-peptide, respectively. Plasma glucose concentration was quantified by the glucose-peroxidase method (Dr. Lange, Berlin, Germany). The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated according to Matthews et al. (24) .
AT gene expression analyses
Total RNA was isolated from 100 mg of AT, using the RNeasy Lipid Tissue Mini kit (Qiagen, Hilden, Germany) according to manufacturer's protocol, including DNase treatment (Qiagen), and stored at 280°C. Quantity and purity were assessed with a spectrophotometer (NanoDrop 1000; Thermo Fisher Scientific, Wilmington, DE) as well as Bioanalyzer 2100 (Agilent technologies, Santa Clara, CA). Two VAT samples from patients with GDM had poor RNA quality (RNA integrity number , 6) and were excluded from analyses. cDNA was synthesized with 300 ng of RNA using the iScript kit (Bio-Rad, Hercules, CA), including necessary controls (no reverse transcription). Using TaqMan technology with a 7500 instrument (Applied Biosystems, Waltham, MA), quantitative real-time PCR was performed in triplicate and all plates included respective controls (no template, internal control sample). A predesigned exon-exon spanning TaqMan primer assay for IR was obtained from Applied Biosystems (assay no. Hs00961554_ m1). Target gene expression was normalized to the housekeeping gene peptidylprolyl isomerase A (PPIA; assay no. Hs99999904_ m1) using the 2 2DCt method, including correction for amplification efficiency calculated from standard curves of each primer set. PPIA had stable expression, as in previous analyses (25) , and showed identical mRNA levels (6 SEM) 
AT protein expression analyses
Total protein was isolated from 80 mg of AT, using the Minute Total Protein Extraction kit (Invent Biotechnologies, Plymouth, MN) and quantified using the Bradford assay (BioRad) according to manufacturers' instructions. Protein analyses were performed in subgroups with sufficient sample availability (NGT vs. GDM: SAT: n = 17 vs. n = 19, VAT: n = 22 vs. n = 14).
Duplicates were analyzed on different gels accompanied by an internal control sample per run for final normalization of target protein levels. Equivalent protein amounts (50 mg) were resolved on 8% SDS-PAGE gels using the Mini-Protean electrophoresis system (Bio-Rad) and electrotransferred onto nitrocellulose membranes (0.2 mm) using the Trans-Blot Turbo system (Bio-Rad). Membranes were blocked using 10% skim milk powder in PBS with Tween (PBST) for 2 hours at room temperature and immunoblotted with a primary monoclonal antibody for IR (b chain, catalog no. AM00078PU-N; Acris Antibodies, Herford, Germany) in a 1:200 dilution in blocking solution (5% skim milk powder/PBST) for 2 hours at room temperature and overnight at 4°C. All blots were incubated with secondary horseradish peroxidase-conjugated antibodies (catalog no. ab97046; Abcam, Cambridge, UK) in a 1:5000 dilution in blocking solution (5% skim milk powder/PBST) for 1 hour at room temperature. b-tubulin served as an endogenous control for normalization (catalog no. ab21058; Abcam) and was applied in a 1:1000 dilution in blocking solution (5% skim milk powder/PBST) for 45 minutes at room temperature. Membranes were developed by enhanced chemiluminescence reagent and visualized with the ChemiDoc imaging system (both from Bio-Rad). Results were analyzed using the Image Laboratory software, version 5.0 (Bio-Rad) and are expressed as AU relative to b-tubulin and to the simultaneously run internal control.
DNA methylation analyses
Genomic DNA was extracted from 30 mg of AT and 1 mL of mixed blood-cell phase using the Genomic DNA-Tissue kit and the Quick-gDNA Blood kit (Zymo Research, Irvine, CA), respectively, following manufacturer's protocols. Quantity and purity of DNA were assessed with a NanoDrop (Thermo Fisher Scientific). Bisulfite treatment was performed on 400 ng of DNA using the EZ DNA Methylation-Gold kit (Zymo Research) as recommended by the manufacturer. To explore the DNA methylation profile across IR promoter [-1.5 kb upstream of the transcription start site (TSS)] and intronic regions, methylation assays were analyzed covering the borders of the CpG islands or shore regions and characterized binding sites for activating/inactivating transcription factors, respectively (26) (27) (28) (29) (30) (31) (32) . Genomic data were obtained from the University of California, Santa Cruz (UCSC) Genome browser on February 2009 human GRCh37/hg19 assembly (RefSeq Accession no. NM_000208) (33) . Methylation assays were designed using PyroMark Assay Design software, version 2.0 (Qiagen); detailed information is provided in Table 1 . Pyrosequencing was performed with the PyroMark Q24 pyrosequencer (Qiagen), including bisulfite conversion checks in each assay. Bisulfite-treatment and pyrosequencing assays were tested and reproducibility validated using duplicate samples, various tissue types, and methylation scales (0% to 100%).
Statistical analyses
Statistical analyses were conducted using SPSS, version 24.0 (IBM, Armonk, NY). Data are presented as mean 6 SEM or number (%). Normal distribution of continuous variables was evaluated by Shapiro-Wilk-tests and skewed data were logarithmically transformed to achieve normal distribution, if necessary. Group comparisons were performed by unpaired t test or Mann-Whitney-U test or x 2 or Fisher exact test, as appropriate. analysis of covariance was used to adjust for maternal BMI or newborn sex. Pearson correlation coefficients (R) were calculated to evaluate associations between variables. Potential confounding effects of maternal BMI or newborn sex were verified with partial Pearson correlations. Two-tailed P , 0.05 was considered to indicate statistical significance.
Results

Study cohort
General and specific parameters of mother-child dyads are listed in Table 2 . According to their mean BMI, both groups were classified as overweight before pregnancy. At delivery, women with GDM displayed hyperglycemia, hyperinsulinemia, and higher insulin resistance (according to HOMA-IR) as compared with the NGT group. Likewise, ODM exhibited significantly elevated glucose, and HOMA-IR levels compared with unexposed newborns.
AT IR expression
In comparison with control samples, IR mRNA expression was significantly reduced in both SAT and VAT in women with GDM (NGT vs. GDM: SAT: 74.2 6 3.7 AU vs. 62.6 6 3.7 AU, P = 0.034; VAT: 64.0 6 3.4 AU vs. 52.9 6 5.0 AU, P = 0.029; Fig. 1A ). On average, subjects with GDM had 16% to 17% less mRNA than the NGT group. After adjustment for maternal BMI, only the difference in VAT remained significant (adjusted for prepregnancy BMI: SAT: P = 0.090, VAT: P = 0.039; adjusted for BMI at delivery: SAT: P = 0.063, VAT: P = 0.036).
To evaluate functional consequences of decreased IR mRNA levels in GDM, protein levels of IR were analyzed. In both fat depots, IR protein levels were similarly reduced in women with GDM but statistically significant only in VAT (NGT vs. GDM: SAT: 0.69 6 0.06 AU vs. 0.55 6 0.04 AU, P = 0.060; VAT: 0.71 6 0.06 AU vs. 0.53 6 0.03 AU, P = 0.018; Fig. 1B ). As compared with controls, the GDM group was characterized by 16% to 20% lower IR protein levels in SAT and VAT. The significant group difference in VAT was independent of maternal BMI (adjusted for prepregnancy BMI: VAT: P = 0.041; adjusted for BMI at delivery: VAT: P = 0.012).
In the whole cohort, mRNA levels were significantly positively correlated with IR protein levels in VAT but not in SAT (Fig. 1C and 1D ), independent of maternal BMI (adjusted for prepregnancy BMI: VAT: R = 0.47, P = 0.004; adjusted for BMI at delivery: VAT: R = 0.43, P = 0.009). SAT and VAT IR protein levels were inversely associated with maternal prepregnancy BMI and fasting glucose at delivery (Table 3 ). In addition, VAT IR protein levels correlated inversely with maternal BMI, insulin and HOMA-IR levels at delivery. Moreover, VAT IR protein levels were inversely related to CB glucose, insulin, and HOMA-IR levels, independent of newborn sex (Table 3) .
Overall DNA methylation patterns across IR promoter and intronic regions in ATs and blood cells
The IR promoter region contains a high amount of CpG dinucleotides with two CpG islands, as defined according to the GRCh37/hg19 assembly in the UCSC Genome browser (33) . Because the DNA methylation pattern of the human IR promoter region has not been described yet, we analyzed its signature in a number of genomic regions, using the mean methylation levels of the whole cohort in all available tissues (i.e., SAT, VAT, MB, and CB; Fig. 2 ). Interestingly, a rather conserved, nontissue-specific DNA methylation pattern was found across tissues (Fig. 2B) . Methylation generally was low (,10%) in the regions covering up to ;1.0 kb upstream of the TSS, but these regions were surrounded by variable methylation levels (#50%) at the borders of CpG island and shore regions (;1.2 kb upstream and ;0.6 kb downstream of the TSS, respectively). Although the DNA methylation pattern of region1 (;1.2 kb upstream of the TSS) was relatively similar across tissues, methylation levels of intron1 (;0.6 kb downstream of the TSS) clearly separated ATs from blood cells (Fig. 2B ). More specifically, CB intron1 showed the highest degree of methylation (#50%) followed by MB (,45%), VAT (,30%), and SAT (,25%).
Specific DNA methylation patterns of IR promoter and intronic regions across maternal ATs and blood cells To verify whether the observed gene expression levels in ATs were associated with the DNA methylation profile, group comparisons and correlation analyses across the whole cohort were performed. Both AT types had a number of alterations in the higher-methylated region1 and intron1 (,50% methylation; Fig. 3A and 3B). In SAT, CpG2-and CpG13-region1 were lower and CpG5-intron1 higher methylated in women with GDM vs. control subjects (Fig. 3A) . Furthermore, the GDM group was characterized by hypermethylation of CpG8-region1 as well as CpG2-and CpG6-intron1 in VAT compared with the NGT group (Fig. 3B) . A positive association was found between methylation at CpG2-region1 in SAT and IR mRNA levels (R = 0.29; P = 0.038). In contrast to these higher-methylated regions, the assays GRE2 and FOXO (binding FOXO1), covering both an inactivating [glucocorticoid response element (GRE)] and an activating (FOXO) transcription factor binding site (TFBS), showed overall low methylation levels (,10%) and no group differences in SAT or VAT ( Fig. 4A and 4B) . Across all subjects, methylation levels at CpG4-GRE2 correlated inversely with gene expression in SAT (R = 20.30; P = 0.040). Similar to the GRE2 and FOXO assays, the regions AP-2 and SP1 and GRE1 displayed overall low methylation levels (,10%). Here, significant group differences were observed in multiple positions ( Fig. 5A and 5B). In SAT, higher methylation was present at CpG2-AP-2 and SP1 and CpG9-GRE1, both located in TFBS, in subjects with GDM compared with control subjects (Fig. 5A) . On the contrary, the GDM group was characterized by lower methylation at CpG2-AP-2 and SP1 (in the AP-2 binding site) and various CpG dinucleotide sites of GRE1 in VAT (Fig. 5B) . Correlation analyses revealed an inverse relationship of methylation of CpG3-AP-2 and SP1 with IR mRNA levels in SAT (R = 20.29; P = 0.043). In contrast, DNA methylation of CpG1-and CpG5-GRE1 in SAT as well as CpG2-, CpG4-, and CpG5-GRE1 in VAT were all positively associated with respective IR gene expression (all R , 0.34; P , 0.05). There were no group differences in MB DNA methylation in region1, AP-2 and SP1 and intron1, but there were a few alterations in GRE2, FOXO, and GRE1 (Figs. 3C and 5C ). As observed in GRE1 in VAT (Fig. 5B) , a number of significant differences were found (namely, CpG1-2, CpG7, and CpG9). In contrast to VAT, hypermethylation occurred here in the GDM but not in the NGT group (Fig. 5C ). Despite similarities in the overall DNA methylation patterns across all investigated maternal tissues, the variability was different, with higher variation in ATs vs. MB (Figs. 3A-3C and 5A-5C ). Furthermore, correlations between CpG dinucleotide sites of ATs and MB were rare. For example, of all significantly different CpG dinucleotides between women with GDM and those with NGT, only CpG13-region1 methylation level correlated between SAT and MB (R = 0.36; P = 0.010).
Specific DNA methylation patterns of IR promoter and intronic regions in CB of Offspring in the NGT and GDM Groups CB DNA methylation showed no alterations in GRE2 and FOXO (Fig. 4D) , but there were a few significant differences in the other investigated regions (Figs. 3D and  5D ). Independent of newborn sex, ODM had higher methylation levels at CpG2-region1 and lower methylation at CpG1-, CpG2-, and CpG5-intron1 compared with those of unexposed newborns (Fig. 3D) . Moreover, CpG2-(in TFBS) and CpG4-AP-2 and SP1 were hypermethylated and CpG8-GRE1 (in TFBS) was hypomethylated in CB of ODM vs. that of control subjects (Fig. 5D) . Cross-tissue comparisons indicated that the variability of DNA methylation in CB was more similar to MB than to maternal ATs, with relatively tight methylation ranges (Figs. 3-5) .
Sex-adjusted correlation analyses with neonatal metabolic and endocrine parameters revealed that HOMA-IR and insulin levels were not related to CB DNA methylation. In contrast, CB glucose was positively associated with methylation of CpG2-AP-2 and SP1 (R = 0.29; P = 0.044) and inversely with methylation of CpG3-GRE1 (R = 20.30; P = 0.032).
Discussion
GDM is characterized by cellular insulin resistance; the underlying molecular mechanisms, however, largely remain unclear (5, 34) . The presented data provide evidence that expression of IR on the transcriptional and protein level is decreased at delivery in the major fat depots of women with GDM as compared with matched control subjects. In particular, there were significant alterations in VAT IR expression in subjects with GDM, even independent of the BMI, whereas SAT IR expression appeared to be related to maternal BMI than diabetes per se. Moreover, our data indicate that VAT IR protein levels are variously associated with glucose metabolism and insulin resistance in both mother and offspring, linking a molecular defect to adverse materno-fetal outcomes.
In addition, our data demonstrate that the overall DNA methylation patterns across investigated IR promoter regions are very similar in maternal SAT, VAT, MB, and CB. Subjects with GDM, however, had multiple specific alterations of DNA methylation across investigated tissues. In general, these differences were of small effect size and rarely associated with respective IR mRNA levels. Similar to maternal patterns, DNA methylation of CB cells showed multiple alterations, including TFBS of activating/inactivating factors.
In SAT and VAT, IR dysregulation was present in patients with GDM compared with the BMI-matched NGT group. However, adjustment for BMI resulted in a nonsignificant difference regarding SAT mRNA levels, indicating that maternal overweight or obesity per se may have an effect on IR gene expression in SAT. This is in line with a previous study in which a progressive decrease of IR mRNA levels in SAT was found across nonobese and obese women with GDM or NGT (12) . Interestingly, the same study indicated there might be an additive effect of obesity and diabetes on IR gene expression in SAT, which may apply here as well. In parallel to the observed mRNA profile, SAT IR protein levels were equally reduced in subjects with GDM , showing a clear trend toward significance. Because SAT IR protein levels correlated inversely with maternal BMI and glucose at delivery, synergistic effects of maternal adiposity and glucose intolerance might be causal here. To date, in only two studies, to our knowledge, was IR protein expression in SAT investigated and inconsistent results found. In obese subjects, protein levels of IR were similar between diettreated GDM and weight-matched pregnant women serving as controls (10) . In contrast, Colomiere et al. (12) found significantly decreased IR protein levels in SAT of nonobese and obese women with GDM compared with subjects with NGT. These controversial findings may originate from limited sample numbers and/or differences in the degree of glucose intolerance of the investigated subjects with GDM. Possibly, SAT IR protein levels could have been influenced by a synergistic effect of overweight or obesity and insulin resistance, because, for example, no difference was observed by comparing nonobese vs. obese women with NGT (12) . Similar additive effects may occur in VAT IR expression; however, our data indicate that the GDM impact is more pronounced in this fat depot, because adjustment for BMI had no major effect on group differences in mRNA and protein levels. Still, robust correlations of VAT IR expression were present with both maternal BMI and glycemia and insulin resistance, suggesting influences of or consequences for both characteristics. Interestingly, VAT IR protein levels were clearly related to glucose, insulin, and HOMA-IR levels in the offspring. This may indicate a molecular mechanism through which defects in VAT ultimately affect fetal hyperglycemia and insulin resistance. Increased concentrations of glucose and insulin have variously been suggested as key players involved in programming of later disorders or diseases (18) . Furthermore, it is worth mentioning that no relationships were observed between SAT and VAT IR protein levels and oral glucose tolerance test glucose values during midpregnancy, potentially confirming earlier observations on the particular importance of late pregnancy glucose metabolism for critical outcomes (21) . Taken together, VAT insulin resistance through reduced IR expression might be a specific etiopathogenic factor in GDM.
To our knowledge, this is the first study characterizing the human IR promoter and intron 1 DNA methylation patterns, in general. The explored IR promoter region (26, 27) had overall low methylation levels, which is commonly associated with CpG island promoters allowing transcriptional initiation (17) . Interestingly, all addressed tissues had a similar methylation profile across the investigated genome sites, with the exception of the intron1 region. Moreover, the interindividual variation in the intron1 region was particularly high as compared with the other locations. Such findings could point to a biomarker potential in this locus, which could become beneficial for the advancement of clinical and experimental approaches.
Site-specific DNA methylation levels were altered at various CpG dinucleotides in SAT and VAT in women with GDM compared with control subjects. Despite some group differences in region1 and intron1, however, only one positive correlation was observed between methylation and mRNA levels. Region1 includes a DNaseI hypersensitivity site (according to UCSC), which generally is associated with gene regulatory elements (35) . Furthermore, potential functions of intronic regions in transcriptional regulation have been highlighted before (36, 37) . Thus, a regulatory role appears possible but needs additional investigation. Although GDM was not characterized by methylation changes in GRE2 and FOXO, differences were present around binding sites for AP-2 and, particularly, GR (GRE1 region) in both fat depots. Interestingly, more and stronger alterations were observed in VAT than SAT. Although CpG methylation levels in TFBS were not significantly related to respective mRNA levels, the surrounding CpG dinucleotides may also influence binding ability. Hence, the observed positive (multiple CpG dinucleotides in GRE1 in SAT and VAT) and inverse (CpG3-AP-2 and SP1 in SAT) correlations are in agreement with the proposed function of these transcription factors (GRE: inactivating; AP-2/SP1: activating).
Collectively, our data indicate that GDM is associated with various small alterations in IR DNA methylation, even around TFBS, in both ATs. Hence, it can be hypothesized that other epigenetic, regulatory regions or mechanisms may be affected in GDM, leading to IR downregulation. In addition to (or in combination with) potential differences in DNA methylation levels of tissuespecific enhancers, repressors, and so forth, such mechanisms may also include alterations of histone modifications, noncoding RNAs affecting mRNA stability, and/or differential activity of activating/ inactivating transcription factors.
Despite a similar DNA methylation pattern across all investigated maternal tissues, MB showed overall less variability, and correlations patterns between MB and ATs were rare, indicating that MB (blood cells) is not an ideal representative or diagnostic tissue for the fatspecific DNA methylation profile.
Similarly, various studies have shown alterations of DNA methylation in CB of ODM, although functional and/or diagnostic or predictive consequences remain to be established (20, 38, 39) . Accordingly, several rather small differences were found in the present cohort. In ODM, however, we observed hypermethylation at CpG dinucleotides of activating TFBS (namely, AP-2 and SP1) accompanied by hypomethylation at an inhibiting TFBS (GRE). Whether these changes relevantly affect gene transcription, are also present in other tissues of ODM, and/or have the potential to serve as predictive biomarkers remains to be investigated.
Finally, some limitations should be considered. The analyses here are restricted to whole tissue samples, as in other studies (10, 11, 12, 19) and therefore may be influenced by differences in cell-type composition between tissues and subjects. Furthermore, different treatment modalities in GDM subjects (i.e., diet vs. insulin therapy) may have affected molecular results. Because the study focus was on the characterized promoter region, additional investigations should address other regulatory regions (e.g., distal enhancer regions) to evaluate potential alterations of the DNA methylation pattern.
In conclusion, decreased IR expression in ATs, especially in VAT, appears to be critically involved in GDM etiopathophysiology. Accompanying alterations of IR promoter methylation show moderate involvement in respective gene transcription. DNA methylation patterns in CB of affected ODM are similarly altered. Therefore, diagnostic or predictive potentials and, especially, a specific and critical role of maternal visceral adiposity, respective (epigenetic) IR alterations in GDM, and consequences for the offspring outcome should be further explored.
